What is Dilon Technologies?
Founded in 1997, Dilon Technologies, Inc. operates as a specialized leader in the medical device industry. The company is primarily recognized for its pioneering work in hemostasis, cancer detection, and advanced airway management solutions. By integrating cutting-edge manufacturing processes with rigorous clinical standards, Dilon Technologies has established itself as a critical partner for healthcare providers seeking to improve patient outcomes through technological innovation. Its market position is defined by a commitment to precision engineering and a robust portfolio of diagnostic and therapeutic tools that address some of the most pressing challenges in modern medicine.
How much funding has Dilon Technologies raised?
Dilon Technologies has raised a total of $19.6M across 7 funding rounds:
Debt
$660K
Debt
$1.9M
Debt
$4M
Private Equity
$1.9M
Debt
$350K
Private Equity
$9M
Private Equity
$1.9M
Debt (2008): $660K, investors not publicly disclosed
Debt (2011): $1.9M, investors not publicly disclosed
Debt (2012): $4M, investors not publicly disclosed
Private Equity (2017): $1.9M, investors not publicly disclosed
Debt (2020): $350K backed by PPP
Private Equity (2025): $9M with participation from JGB Management
Private Equity (2025): $1.9M, investors not publicly disclosed
Key Investors in Dilon Technologies
JGB Management
JGB Management Inc. is an alternative asset management firm established in 2005 by Brett Cohen. The company specializes in investing in niche credit-oriented situations and provides strategic investment solutions tailored for clients seeking unique opportunities in the credit market.
PPP
Public-Private Partnership
Undisclosed Investors
What's next for Dilon Technologies?
With the recent infusion of $1.9M, Dilon Technologies is strategically positioned to accelerate its product development pipeline and expand its footprint in global markets. The company is expected to prioritize the scaling of its cancer detection technologies, which remain a core pillar of its value proposition. Furthermore, the enterprise-level nature of this funding suggests a focus on operational efficiency and potential inorganic growth opportunities. As the firm moves into this next phase of development, stakeholders will be closely monitoring its ability to translate this capital into sustained market share gains and technological breakthroughs in the medical device space. The strategic deployment of these funds will likely involve enhancing manufacturing capabilities and deepening its research initiatives to maintain its competitive edge in the evolving healthcare technology sector.
See full Dilon Technologies company page
